Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Aarti Pharmalabs
Mid Cap•2,095 Employees•IPO 2023
Current Price
₹650.85
-27.8 (-4.1%)Updated
Today's Range
646
₹650.85
681.55
52 Week Range
52W Low₹574.45
52W High₹971.00
₹650.85
Downside13.30%
Upside49.19%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹6,552.89 Cr
Market Cap
Total market value of companyP/E Ratio
26.92
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
3.67
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹26.45
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
5.76%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
17.40%
ROCE
Return on Capital Employed. >15% is goodNet Margin
12.58%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
-%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
-30.50%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
-10.70%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.21
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹219.55
Book Value
Net asset value per shareDividend Yield
0.68%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
42.90%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •Operating Profit Margin of 19.20% indicates effective cost management.
- •Return on Capital Employed at 17.40% demonstrates strong asset management.
Weaknesses
5 points- •Significant -30.50% decline in quarterly sales raises concerns about revenue generation.
- •Quarterly profits fell by -10.70%, impacting short-term earnings consistency.
Opportunities
5 points- •Global demand for pharmaceuticals, driven by aging population, presents market expansion.
- •Continuous R&D advancements offer avenues for new product innovation and portfolio diversification.
Threats
5 points- •Intense competition from larger players could pressure market share and pricing.
- •Stringent, evolving regulatory policies pose risks of increased compliance costs.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
Recent Insider Transactions
| Insider Name | Transaction Date | Filing Date | Total Shares | Change | Price | Action |
|---|---|---|---|---|---|---|
Anushakti Enterprises Pvt Limited | 14 Feb 2025 | 14 Feb 2025 | 29.93 L | 20,250 | ₹734.11 | BUY |
Narendra J Salvi | 14 Feb 2025 | 14 Feb 2025 | 8,154 | 8,000 | ₹721.74 | SELL |
Orchid Family Trust | 20 Feb 2025 | 20 Feb 2025 | 7.30 L | 50,000 | ₹811.38 | SELL |
Tulip Family Trust | 20 Feb 2025 | 20 Feb 2025 | 7.42 L | 55,000 | ₹821.86 | SELL |
Orchid Family Trust | 20 Mar 2025 | 20 Mar 2025 | 7.04 L | 25,000 | ₹776.23 | SELL |
Orchid Family Trust | 20 Mar 2025 | 20 Mar 2025 | 7.29 L | 500 | ₹769.23 | SELL |
Tulip Family Trust | 21 Mar 2025 | 24 Mar 2025 | 7.08 L | 20,000 | ₹781.72 | SELL |
Orchid Family Trust | 20 Mar 2025 | 24 Mar 2025 | 6.80 L | 24,500 | ₹782.29 | SELL |
Tulip Family Trust | 20 Mar 2025 | 24 Mar 2025 | 7.28 L | 15,000 | ₹784.22 | SELL |
Nikhil Parimal Desai | 26 Mar 2025 | 27 Mar 2025 | 7.17 L | 50,000 | ₹727.62 | SELL |
Parimal Hasmukhlal Desai | 26 Mar 2025 | 27 Mar 2025 | 3.50 L | 50,000 | ₹725.59 | SELL |
Renil Rajendra Gogri | 25 Mar 2025 | 08 Apr 2025 | 25.43 L | 2.50 L | ₹734 | SELL |
Arti Rajendra Gogri | 25 Mar 2025 | 08 Apr 2025 | 4.55 L | 20,000 | ₹724 | SELL |
Narendra J Salvi | 21 May 2025 | 22 May 2025 | 8,951 | 6,000 | ₹841.46 | SELL |
Orchid Family Trust | 28 May 2025 | 29 May 2025 | 6.50 L | 30,000 | ₹878.74 | SELL |
Tulip Family Trust | 28 May 2025 | 29 May 2025 | 6.88 L | 20,000 | ₹881.47 | SELL |
Orchid Family Trust | 30 May 2025 | 02 Jun 2025 | 6.30 L | 20,000 | ₹889.31 | SELL |
Orchid Family Trust | 30 May 2025 | 02 Jun 2025 | 6.10 L | 20,000 | ₹909.98 | SELL |
Tulip Family Trust | 30 May 2025 | 02 Jun 2025 | 6.47 L | 40,000 | ₹890.59 | SELL |
Orchid Family Trust | 06 Jun 2025 | 06 Jun 2025 | 6.10 L | 20,000 | ₹926.16 | SELL |
Tulip Family Trust | 06 Jun 2025 | 06 Jun 2025 | 6.08 L | 40,000 | ₹919.11 | SELL |
Orchid Family Trust | 11 Jun 2025 | 11 Jun 2025 | 5.80 L | 30,000 | ₹927.52 | SELL |
Tulip Family Trust | 12 Jun 2025 | 13 Jun 2025 | 5.83 L | 25,000 | ₹933.39 | SELL |
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹744.03 | +₹93.18 | +14.32% |
| R3 | ₹708.48 | +₹57.63 | +8.86% |
| R2 | ₹695.02 | +₹44.17 | +6.79% |
| R1 | ₹672.93 | +₹22.08 | +3.39% |
| PIVOT | ₹659.47 | 8.62 | 1.32% |
| CURRENT | ₹650.85 | - | - |
| S1 | ₹566.28 | -₹84.57 | -12.99% |
| S2 | ₹601.83 | -₹49.02 | -7.53% |
| S3 | ₹623.92 | -₹26.93 | -4.14% |
| S4 | ₹637.38 | -₹13.47 | -2.07% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+84.5% vs avg
2.73L
(13 Mar 2026)Delivery %-1.9% vs avg
48.9%
(13 Mar 2026)Avg Volume (20D)20-day average
1.48L
(13 Feb - 13 Mar)Avg Delivery %Trend ↑
50.8%
(13 Feb - 13 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Shilpa Medicare Ltd
234.00 %
Highest Dividend Yield
Procter & Gamble Health Ltd
3.64 %
Peer Comparison
| Company Name |
|---|
 Aether Industries Ltd |
 Blue Jet Healthcare Ltd |
 FDC Ltd |
 Marksans Pharma Ltd |
 Procter & Gamble Health Ltd |
 Sanofi India Ltd |
 Senores Pharmaceuticals Ltd |
 Sequent Scientific Ltd |
 Shilpa Medicare Ltd |
 Sun Pharma Advanced Research Company Ltd |
 Strides Pharma Science Ltd |
 Sun Pharmaceutical Industries Ltd |
 Supriya Lifescience Ltd |
 Zota Health Care Ltd |
About
Aarti Pharmalabs Ltd
Aarti Pharmalabs Limited is a prominent Indian pharmaceutical company specializing in the manufacturing and global distribution of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and xanthine derivatives. Their diverse portfolio caters to a wide range of therapeutic areas, contributing to the production of various medications.
The company's API production supports a broad spectrum of medical needs, including cardiovascular health, asthma treatment, cancer therapies, anticoagulants, diabetes management, arthritis care, central nervous system (CNS) agents, skincare products, overactive bladder treatments, calcimimetics, decongestants, anti-thalassemics, analgesics, and ophthalmologic medications. This wide-ranging production demonstrates a commitment to addressing diverse health concerns through the supply of essential pharmaceutical components.
Beyond API production, Aarti Pharmalabs also offers contract development and manufacturing services (CDMO) for drug substance projects. This service caters to other pharmaceutical companies needing assistance with the development and production of their drug substances, expanding the company's role in the pharmaceutical industry beyond its own product lines.
Further strengthening their market presence, the company manufactures and sells a variety of intermediates and xanthine derivatives. These include crucial compounds like caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline, showcasing expertise in specialized chemical synthesis. In addition, they produce acidic and allied products, such as sulphuric acid, sulphur trioxide, oleum, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate, demonstrating a comprehensive range of chemical manufacturing capabilities.
Established in 2019 and headquartered in Mumbai, India, Aarti Pharmalabs Limited, previously known as Aarti Organics Limited, has rapidly established itself as a significant player in the global pharmaceutical supply chain, leveraging its extensive manufacturing capabilities and diverse product portfolio to meet the growing demand for high-quality pharmaceutical ingredients worldwide.
COMPANY FACTS - AARTIPHARM
Registered Address
2nd Floor, 204, Udyog Kshetra, Mulund - Goregaon Link Rd, Mulund (W)
Mumbai
MAHARASHTRA
IN
Tel: 912269436100
Website:https://www.aartipharmalabs.com/
Investor Relations:http://www.aartipharmalabs.com/financialinformation
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 2,095
IPO Date: 30/01/2023
MANAGEMENT - AARTIPHARM
Shri. Rashesh Gogri
Chairman of the Board
Mr. Jeevan Mondkar
Company Secretary and Compliance Officer
Smt. Hetal Gala
Director
Mr. Chetan Gandhi
Director
Mr. Rajendra Gogri
Director
Shri. Narendra Salvi
Director
Smt. Nehal Garewal
Non-Executive Non-Independent Director
Shri. Pradeep Thakur
Non-Executive Independent Director
Investor Questions Answered
Aarti Pharmalabs Ltd (AARTIPHARM) Stock FAQs
Get answers to the most common questions about Aarti Pharmalabs Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Aarti Pharmalabs Ltd (AARTIPHARM) is ₹650.85. Today, the stock has declined by ₹27.80 (4.10%), trading in a range of ₹646 to ₹681.55. The stock opened at ₹674 with a trading volume of 2,73,323 shares.
Aarti Pharmalabs Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹6,552.89 crores, P/E ratio of 26.92, ROE of 5.76%, and ROCE of 17.40%. The dividend yield stands at 0.68%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Aarti Pharmalabs Ltd (AARTIPHARM) is ₹971, while the 52-week low is ₹574.45. Currently trading at ₹650.85, the stock is 19.3% away from its 52-week low and 33.0% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Aarti Pharmalabs Ltd stock at ₹650.85 depends on multiple factors. The stock is currently trading with a P/E ratio of 26.92 and P/B ratio of N/A. Today's performance shows a loss of 4.10%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Aarti Pharmalabs Ltd offers a dividend yield of 0.68%, which means for every ₹100 invested at the current price of ₹650.85, you can expect to receive approximately ₹0.68 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Aarti Pharmalabs Ltd's key financial metrics include: P/E Ratio: 26.92, P/B Ratio: N/A, ROE: 5.76%, ROCE: 17.40%, Dividend Yield: 0.68%, EPS: ₹26.45, Book Value: ₹219.55, Debt-to-Equity: 0.21, and Current Ratio: N/A. The company's market cap stands at ₹6,552.89 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Aarti Pharmalabs Ltd stock opened at ₹674 and is currently trading at ₹650.85, showing a decline of ₹27.80 (4.10%). The intraday high is ₹681.55 and low is ₹646. The trading volume stands at 2,73,323 shares, indicating moderate market participation today.
Aarti Pharmalabs Ltd has a Price-to-Earnings (P/E) ratio of 26.92, which means investors are willing to pay ₹26.92 for every ₹1 of earnings. With an EPS of ₹26.45, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Aarti Pharmalabs Ltd has a market capitalization of ₹6,552.89 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹650.85) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Aarti Pharmalabs Ltd has a book value of ₹219.55 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹650.85, which is 196.4% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Aarti Pharmalabs Ltd has a Return on Equity (ROE) of 5.76% and Return on Capital Employed (ROCE) of 17.40%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Aarti Pharmalabs Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Aarti Pharmalabs Ltd has a debt-to-equity ratio of 0.21, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Aarti Pharmalabs Ltd has an Earnings Per Share (EPS) of ₹26.45, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹650.85 and P/E ratio of 26.92, investors are paying 26.92 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Aarti Pharmalabs Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Aarti Pharmalabs Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Aarti Pharmalabs Ltd stock, consider: 1) Fundamental Analysis - Review P/E (26.92), ROE (5.76%), debt-to-equity (0.21), and growth rates. 2) Technical Analysis - Check 52-week range (₹574.45 - ₹971.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹650.85) with book value (₹219.55) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Aarti Pharmalabs Ltd share is ₹5.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹650.85 is 12917x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Aarti Pharmalabs Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹574.45 - ₹971.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.21 indicates leverage. 4) Liquidity Risk - Based on trading volume of 2,73,323 shares. 5) Valuation Risk - P/E of 26.92 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Aarti Pharmalabs Ltd operates in the industry with key metrics: P/E ratio of 26.92, ROE of 5.76%, market cap of ₹6,552.89 crores, and dividend yield of 0.68%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.21), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Aarti Pharmalabs Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹650.85, with a 52-week range of ₹574.45 to ₹971.00. Based on fundamentals like P/E (26.92), ROE (5.76%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Aarti Pharmalabs Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹650.85. 2) Fundamental Deterioration - Declining ROE (currently 5.76%), increasing debt (D/E: 0.21), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Aarti Pharmalabs Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.68%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu